齐鲁晚报.齐鲁壹点记者郭蕊通讯员陈晨 近日，济南市第三人民医院心血管内科一病区主任杨兵带领团队成功完成首例房颤脉冲电场消融术，此次手术标志着医院在心律失常介入治疗领域取得重 大突破，为济南东部区域房颤患者提供了更先进的治疗选择。 患者为71岁老年男性，因发作性心悸、胸闷、头晕入院，经检查确诊为"阵发性心房颤动"。杨兵根据患者病情，请北京安贞医院全国知名专家会诊，并与 患者及家属充分沟通后，决定采用脉冲电场消融(PFA)技术进行治疗。 脉冲电场通过不可逆电穿孔机制选择性破坏心肌细胞，对血管、神经、食道等周围组织损伤风险极低。大量案例显示，接受脉冲电场消融术后不仅心跳恢 复正常，也避免了传统手术可能引发的多种并发症。 高效快捷，术后恢复无忧 手术时间可缩短至1小时左右，患者术后1-2天即可出院。脉冲电场消融对房颤术后复发患者同样有效，单次脉冲即可实现透壁性损伤，显著提升患者治疗 成功率。 手术在全麻的方式下进行，脉冲电场消融时间约半小时，较传统的射频消融时间(一般约90分钟)大大缩短，手术顺利，术后患者无任何不适，亦未再发作 房颤，无任何并发症发生，手术达到了预期效果。术后8小时，患者已能下床活动，身体恢复良好。 ...

Summary of Pulse Biosciences (PLSE) FY Conference Call - August 13, 2025 Company Overview - **Company**: Pulse Biosciences - **CEO**: Paul Le Violette - **CFO**: John Skinner - **Industry**: Medical Technology, specifically focusing on pulsed electric field (PFA) therapies Core Points and Arguments - **Therapeutic Platform**: Pulse Biosciences is focused on a life-changing therapeutic platform utilizing nanosecond PFA technology to treat various diseases, including atrial fibrillation (AFib) and benign thyroid nodules [4][5][6] - **Market Potential**: The company targets multiple markets, including thyroid interventions, cardiac surgery, and electrophysiology (EP) ablation, with a total addressable market of approximately $6 billion, expected to double over time [19][20] - **PFA Technology**: The unique aspect of Pulse's PFA technology is its ability to deliver shorter pulse durations (in billionths of a second), which allows for non-thermal tissue ablation, reducing the risk of thermal damage and improving clinical outcomes [8][9][17] - **Clinical Applications**: The company has multiple FDA clearances and breakthrough designations for its technologies, indicating strong clinical validation and potential for market entry [10][11] Key Market Segments 1. **Thyroid Interventions**: - Targeting benign thyroid nodules, with 250,000 patients diagnosed annually in the U.S. and 150,000 leading to surgical removal [25][26] - Aims to convert surgical procedures into less invasive alternatives, preserving thyroid function and reducing recovery time [27][28] - Currently in a pilot program with plans for a limited launch across 10 centers [29][30] 2. **Cardiac Ablation**: - Focused on patients undergoing open-heart surgery who also have preoperative AFib, with only 25-30% currently receiving ablation therapy [32] - The technology aims to improve the efficiency and effectiveness of existing radiofrequency ablation methods [33] 3. **Electrophysiology (EP) Market**: - The largest market segment, with significant potential for NSPFA to enhance treatment speed and safety compared to first-generation PFA technologies [36][39] Financial Position - **Strong Balance Sheet**: The company reported over $100 million in cash at the end of the quarter, enabling execution of its strategic plans [14][40] Strategic Approach - **Hybrid Market Entry Strategy**: The company plans to pursue a combination of direct market entry and partnerships, focusing on capital-efficient approaches to maximize market penetration [20][21] Challenges and Considerations - **Clinical Data and Reimbursement**: The company acknowledges the importance of clinical data to drive adoption and is actively working on reimbursement strategies to facilitate market entry [43][47] - **Existing Codes**: There are existing codes for irreversible electroporation that could be leveraged for reimbursement, although thyroid is not currently an approved indication [47][48] Conclusion - **Future Outlook**: Pulse Biosciences is positioned for growth with its innovative PFA technology, targeting significant unmet needs in the medical market, and is optimistic about its potential to transform treatment paradigms in multiple therapeutic areas [39][41]